JKN2304
/ Joincare
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 30, 2026
Phase 2a trial of JKN2304, an inhaled muscarinic antagonist/β2-adrenoceptor agonist (MABA), in COPD
(ERS 2026)
- No abstract available
P2a data • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases
March 05, 2026
Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD
(clinicaltrials.gov)
- P2 | N=42 | Completed | Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd
New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1